AMETEK INC/
AMETEK is a global manufacturer of electronic instruments and electromechanical devices, serving process, power, industrial, aerospace, medical, automation and other markets. Headquartered in Berwyn, Pennsylvania, it sells products worldwide through two operating groups: Electronic Instruments (EIG) and Electromechanical (EMG). EIG makes analytical, test and measurement instruments, including process analyzers, sensors, power monitoring equipment, aerospace instrumentation and measurement systems. EMG makes precision motion control solutions, medical components and devices, thermal management systems, specialty metals, motors and electrical interconnects, and provides aviation maintenance, repair and overhaul services. AMETEK earns money by selling products and services through direct sales forces, specialized distributors and sales representatives.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AME in the last 30 days.
See all $AME insider activity →AMETEK INC/ (AME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMETEK Announces Record Third Quarter 2026 Results and Raises Full Year Guidance Berwyn, Pa., Nov 3, 2026 – AMETEK, Inc. (NYSE: AME) today announced its financial results for the third quarter ended September 30, 2026. AMETEK’s third quarter 2026 sales were a record
AMETEK (NYSE: AME) reported record Q3 2026 sales of $2.22B, up 17% YoY, with GAAP EPS of $1.85 and adjusted EPS of $2.21. Operating income rose 20% to $584.9M. The company raised full-year guidance, expecting mid-teens sales growth and adjusted EPS of $8.53-$8.57, up from prior guidance of $8.20-$8.30.
U.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.
Over the past 7 days, AlphAI's AI scored 11 news stories mentioning AME (AMETEK INC/). Coverage has skewed bullish: 10 bullish, 1 neutral, and 0 bearish.
Recent AME coverage spans financial news, earnings and mergers & acquisitions.
Guidance raise plus record Q3 results likely supports upward repricing of AME earnings expectations.
Raised full-year EPS range and guided Q4 sales and EPS higher, supporting a bullish repricing versus prior guidance.
Maintenance with no stated target change implies limited incremental impact.
Bias modestly positive on fundamentals due to strong quarter, record backlog, and raised guidance, but with guidance implying slower organic growth later.
Analyst price‑target increase suggests slight upside pressure on AMETEK.
AlphAI scores every news story that mentions AME with an AI model for sentiment and relevance, and aggregates insider trades from AMETEK INC/'s SEC EDGAR Form 4 filings. Figures refresh continuously.
AMETEK INC/ (AME) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AMETEK Announces Record Third Quarter 2026 Results and Raises Full Year Guidance Berwyn, Pa., Nov 3, 2026 – AMETEK, Inc. (NYSE: AME) today announced its financial results for the third quarter ended September 30, 2026. AMETEK’s third quarter 2026 sales were a record
4 min readAMETEK (NYSE: AME) reported record Q3 2026 sales of $2.22B, up 17% YoY, with GAAP EPS of $1.85 and adjusted EPS of $2.21. Operating income rose 20% to $584.9M. The company raised full-year guidance, expecting mid-teens sales growth and adjusted EPS of $8.53-$8.57, up from prior guidance of $8.20-$8.30.
6 min readU.S. analyst updates on October 12th, 2026, show a cautious outlook with more price-target reductions than increases. Financials, insurance, and real estate saw conservative valuations, while tech sentiment was mixed. Energy received stronger support, and healthcare saw positive coverage.
6 min readAMETEK (AME) is a top holding of Mario Gabelli's GAMCO Investors, with a $131.7M stake. The company, which makes sensors and instruments, trades at a forward P/E of 29.7. Analysts expect 12.5% EPS growth in 2026 and 14% in 2027. Recent earnings showed 15% sales growth and 17% EPS growth, with a record order backlog. Management raised full-year guidance but expects slower growth in the second half.
7 min readCitigroup raised its price target for AMETEK (AME) from $261 to $263. The stock is currently trading at $248.58, up 0.43% on the day but down 1.33% over the past year. Morgan Stanley also recently increased its target to $275 from $245.
1 min readAMETEK's average stock price target increased from $284 to $285.76 by 17 analysts, with a range of $255 to $318. This implies a 15% upside from the Oct. 8 closing price. The consensus rating remains 'Buy' among 23 analysts, with 15 Buys, 7 Holds, and 1 Sell.
1 min readDA Davidson reiterated a Buy rating and $285 price target for Ametek Inc. (NYSE:AME) after its acquisition of Indicor Instrumentation, citing strategic alignment and strong financial health. The stock has gained 41% over the past year, with analysts revising earnings upwards and maintaining strong dividend payments. Ametek recently reported Q2 2026 earnings of $2.09 per share on revenue of $2.04 billion, exceeding expectations and raising its full-year outlook.
2 min readAMETEK (AME) completed a $5.0B cash acquisition of Indicor Instrumentation. The company reported record Q2 sales of $2.04B, up 15% YoY, and raised full-year guidance. Indicor is expected to add $350M to 2026 sales and be modestly accretive to earnings. The deal aligns with AMETEK's existing portfolio and markets.
2 min readBNP Paribas Exane raised Ametek's (NYSE:AME) price target to $290, citing the Indicor deal and projecting $10.60 EPS by 2028. Ametek reported Q2 2026 earnings of $2.09 per share on $2.04B revenue, beating estimates. The company also increased its commercial paper program limit to $3.5B.
2 min readAMETEK (AME) reported Q2 2026 earnings with revenue up 15% to $2.04b, beating expectations. Despite a recent share price decline, long-term returns remain strong. The company raised its outlook, but valuation is debated, with some analysts suggesting undervaluation while others question growth expectations.
2 min read
